In this way we aimed to reduce the frequency of intraprocedural thromboembolic complications with the usual dual antiplatelet protection but rapidly adapt the antithrombotic plan to the more conservative DOAC plus a single P2Y12 inhibitor as proposed for patients with AF who undergo percutaneous coronary interventions. This evidence concerns the gene P2RY12 and atrial fibrillation.